UXBRIDGE, England–(BUSINESS WIRE)–Almirall S.A. (BME: ALM), a global leader in medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has endorsed Ebglyss (lebrikizumab) for the treatment of moderate to severe Atopic Dermatitis (AD) within NHS England.
Lebrikizumab, a monoclonal antibody targeting Interleukin-13, has received approval from the European Commission and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in December 2023. This recommendation marks its availability for prescription across England and Wales.
Atopic Dermatitis affects millions across the UK, impacting daily life significantly,” noted Andrew Proctor, Chief Executive of the National Eczema Society. “The addition of lebrikizumab provides a crucial treatment option for those struggling with moderate to severe forms of the condition, enhancing their quality of life.”
Jorgen Damsbo, General Manager at Almirall UK, highlighted, “NICE’s endorsement underscores lebrikizumab’s efficacy and safety profile, offering patients a promising therapeutic option with a manageable dosing regimen.”
Professor Tony Bewley, Consultant Dermatologist at Barts Health NHS Trust, emphasized the psychosocial toll of AD and welcomed the new treatment option, noting its potential to alleviate symptoms and improve patient outcomes.
Lebrikizumab operates by targeting IL-13, a key driver of the type-2 inflammatory process in AD, thereby addressing symptoms such as skin barrier dysfunction and persistent itching. Its approval represents a significant advancement in the treatment landscape for this chronic condition.
About Lebrikizumab
Lebrikizumab is a monoclonal antibody that binds to IL-13, inhibiting its biological effects involved in the pathogenesis of AD. It offers both monotherapy and combination therapy benefits, supported by clinical data demonstrating efficacy and safety over extended periods.
About Atopic Dermatitis
AD, or atopic eczema, is a chronic inflammatory skin condition characterized by intense itching and skin inflammation. Its prevalence has been increasing, affecting a substantial portion of the population across Europe.
About Almirall
Almirall, a pioneer in medical dermatology, continues to innovate and collaborate to meet the evolving needs of patients worldwide. Founded in 1944 and headquartered in Barcelona, Almirall is committed to transforming patient care through groundbreaking dermatological advancements.
Related Topics:
